Soros Fund Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Soros Fund Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-109,500	Closed	-$793K	–	494
2014 Q1	$793K	Buy	+109,500	New	+$649K	0.01%	246

Other funds holding NWBO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Soros Fund Management's NWBO Position: Q2 2014 in Review

Soros Fund Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2014, closing a stake of 109,500 shares — an estimated $793K sold.

Soros Fund Management first reported a position in NWBO in Q1 2014 and held it in 1 quarter. The position peaked at $793K in Q1 2014. 80 funds tracked by Wall St. Rank hold NWBO as of Q2 2014.

Soros Fund Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2014 after selling out during the quarter.
Soros Fund Management sold 109,500 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2014, an estimated $793K.
Soros Fund Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 1 quarter.
Soros Fund Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $793K in Q1 2014.
80 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2014.

Based on Soros Fund Management's 13F filing for Q2 2014, filed 14 Aug 2014.